Tigecycline: A novel glycylcycline antibiotic

Indian Journal of Pharmacology

Volumn 38, Issue 3, 2006, Pages 217-219

  Gupta, K ^a   Kaushal, S ^a   Chopra, S ^a  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; AZTREONAM; CILASTATIN; GLYCYLCYCLINE DERIVATIVE; RIBOSOME PROTEIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ANTIMICROBIAL ACTIVITY; APPENDICITIS; BACTERIAL INFECTION; BACTERIAL STRAIN; BURN INFECTION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FETOTOXICITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; PNEUMONIA; RIBOSOME; SHORT SURVEY; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT WITHDRAWAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 33745178879     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.25820     Document Type: Short Survey

References (14)

1. Zhanel GG, Homenuik K, Nichol K. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004;64:63-88.
2. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60.
3. th ed. New York: McGraw-Hill; 2006. p. 1174.
4. 2+cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-9.
5. Bergeron J, Ammirati M, Danley D. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet (M), -and Tet (O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-8.
6. Someya Y, Yamaguchi A, Sawai T. A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported not recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter. Antimicrob Agents Chemother 1995;39:247-9.
7. Nathwani D. Tigecycline: Clinical evidence and formulary positioning. Int J Antimicrob Agents 2005;25:185-92.
8. Felmingham D. Tigecyclin: The first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother 2005;17:5-11.
9. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline: A new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71.
10. Livermore DM. Tigecycline: what is it and where should it be used? J Antimicrob Chemother 2005;56:611-4.
11. Van Ogtrop ML, Andes D, Stamstad TJ. In vivo Pharmacodynamic activities of two glycylcylines (GAR-936 and WAY-152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9.
12. th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: 1999.
13. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. Chemotherapy 2005;17:12-22.
14. Frampton JE, Curran MP. Tigecycline. Drugs 2005;65:2023-35.